drugset
drugset / Trial / NCT00733239

Drug Discrimination in Methadone-Maintained Humans Study 2

NCT00733239 ↗

Phase 1 Completed 15 enrolled University of Arkansas National Institute on Drug Abuse (NIDA) · collab
NaSingle-groupDouble-blindBasic science

Summary

This study involves giving psychoactive drugs intramuscularly (injected into the muscle of the upper arm or the hip) and/or orally, and measuring the subject's ability to tell the difference between one drug and another, as well as measuring the effects of the drugs on mood, physiology (e.g., heart rate, blood pressure, respiration rate) and behavior. Each subject will receive 2-4 of the listed interventions.

Timeline

Start
2008-08
Primary completion
2010-10
Completion
2010-10

Publications

Drugs

EvaluationDrugModalityDoseRoute
Subject Cycloserine Small molecule 500 mg Oral
Subject Cycloserine Small molecule 675 mg Oral
Subject Cycloserine Small molecule 750 mg Oral
Subject Diltiazem Small molecule 30 mg Oral
Subject Diltiazem Small molecule 60 mg Oral
Subject Diltiazem Small molecule 120 mg Oral
Subject Gabapentin Small molecule 100 mg Oral
Subject Gabapentin Small molecule 200 mg Oral
Subject Gabapentin Small molecule 400 mg Oral
Subject Isradipine Small molecule 5 mg Oral
Subject Isradipine Small molecule 10 mg Oral
Subject Naloxone Small molecule 0.15 mg Intramuscular
Subject Naloxone Small molecule 0.2 mg Intramuscular
Subject Nifedipine Other / unclassified 5 mg Oral
Subject Nifedipine Other / unclassified 10 mg Oral
Subject Nifedipine Other / unclassified 20 mg Oral
Subject Verapamil Other / unclassified 30 mg Oral
Subject Verapamil Other / unclassified 60 mg Oral
Subject Verapamil Other / unclassified 120 mg Oral

Indications

opiate dependence